olmesartan medoxomil has been researched along with Arteriosclerosis in 9 studies
*Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koike, H; Mizuno, M; Sada, T | 1 |
| de Faire, U | 1 |
| Kim, S; Miyazaki, M; Sakonjo, H; Takai, S | 1 |
| Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Nishida, K; Takeshita, A; Usui, M; Zhao, Q | 1 |
| Buchholz, K; Fliser, D; Haller, H | 1 |
| Horiuchi, M; Ide, A; Iwai, M; Li, JM; Li, Z; Min, LJ; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Koike, H | 1 |
| Miyazaki, M; Takai, S | 1 |
2 review(s) available for olmesartan medoxomil and Arteriosclerosis
| Article | Year |
|---|---|
In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Diuretics; Drug Synergism; Furosemide; Heart; Hemodynamics; Imidazoles; In Vitro Techniques; Kidney; Olmesartan Medoxomil; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors | 2001 |
New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Arteriosclerosis; Diabetic Nephropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2001 |
1 trial(s) available for olmesartan medoxomil and Arteriosclerosis
| Article | Year |
|---|---|
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; C-Reactive Protein; Chemokine CCL2; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Olmesartan Medoxomil; Pravastatin; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vasculitis | 2004 |
6 other study(ies) available for olmesartan medoxomil and Arteriosclerosis
| Article | Year |
|---|---|
Anti-atherosclerotic effects by AT1 receptor blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Arteriosclerosis; Humans; Imidazoles; Olmesartan Medoxomil; Receptor, Angiotensin, Type 1; Tetrazoles | 2003 |
Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Arteriosclerosis; Carotid Arteries; Cholesterol, Dietary; Chymases; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Imidazoles; Intercellular Adhesion Molecule-1; Lipids; Macaca fascicularis; Macrophage Colony-Stimulating Factor; Male; Olmesartan Medoxomil; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Serine Endopeptidases; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vasodilation | 2003 |
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arteriosclerosis; Diabetes Mellitus; Disease Models, Animal; Humans; Hypertension; Imidazoles; Myocardial Infarction; Olmesartan Medoxomil; Rabbits; Ramipril; Rats; Tetrazoles; Time Factors | 2003 |
Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Chemokine CCL2; Chemokines; Cytokines; Disease Progression; Gene Expression Regulation; Gene Targeting; Humans; Hyperlipoproteinemia Type II; Imidazoles; Inflammation; Inflammation Mediators; Injections, Intramuscular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Olmesartan Medoxomil; Random Allocation; Recombinant Fusion Proteins; Sequence Deletion; Single-Blind Method; Tetrazoles | 2004 |
Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Cells, Cultured; Dihydropyridines; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imidazoles; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NADPH Oxidases; Olmesartan Medoxomil; Oxidative Stress; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Superoxides; Tetrazoles; Time Factors | 2005 |
Anti-atherosclerotic efficacy of olmesartan.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Biomarkers; Cholesterol; Cholesterol, Dietary; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Imidazoles; In Vitro Techniques; Inflammation; Lipids; Macaca fascicularis; Male; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2002 |